CN104902905A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN104902905A
CN104902905A CN201380065306.9A CN201380065306A CN104902905A CN 104902905 A CN104902905 A CN 104902905A CN 201380065306 A CN201380065306 A CN 201380065306A CN 104902905 A CN104902905 A CN 104902905A
Authority
CN
China
Prior art keywords
compound
oxo
isopropyl
oxy
pentamethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380065306.9A
Other languages
English (en)
Chinese (zh)
Inventor
S.蔡
B.A.约翰斯
A.斯帕尔滕斯泰因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline China Investment Co Ltd
Original Assignee
GlaxoSmithKline China Investment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline China Investment Co Ltd filed Critical GlaxoSmithKline China Investment Co Ltd
Publication of CN104902905A publication Critical patent/CN104902905A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201380065306.9A 2012-12-14 2013-12-14 药物组合物 Pending CN104902905A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737177P 2012-12-14 2012-12-14
US61/737177 2012-12-14
PCT/US2013/075196 WO2014093941A1 (en) 2012-12-14 2013-12-14 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN104902905A true CN104902905A (zh) 2015-09-09

Family

ID=50935020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380065306.9A Pending CN104902905A (zh) 2012-12-14 2013-12-14 药物组合物

Country Status (20)

Country Link
US (2) US9795619B2 (enExample)
EP (1) EP2931285A4 (enExample)
JP (1) JP2016503030A (enExample)
KR (1) KR20150093819A (enExample)
CN (1) CN104902905A (enExample)
AU (1) AU2013358897B2 (enExample)
BR (1) BR112015013695A2 (enExample)
CA (1) CA2893959A1 (enExample)
CL (1) CL2015001660A1 (enExample)
CR (1) CR20150313A (enExample)
EA (1) EA201590862A1 (enExample)
HK (1) HK1209638A1 (enExample)
IL (1) IL238807A0 (enExample)
MA (1) MA38182A1 (enExample)
MX (1) MX2015007563A (enExample)
PE (1) PE20151326A1 (enExample)
PH (1) PH12015501156A1 (enExample)
SG (2) SG11201503807TA (enExample)
WO (1) WO2014093941A1 (enExample)
ZA (1) ZA201503594B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
SG11201503807TA (en) * 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
PT3019503T (pt) 2013-07-12 2017-11-27 Gilead Sciences Inc Compostos carbamoílpiridona- policíclicos e seu uso para o tratamento de infecções por hiv
NO2865735T3 (enExample) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (enExample) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
KR20170056702A (ko) * 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
US10370405B2 (en) 2015-03-16 2019-08-06 Hetero Labs Limited C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2018042331A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
KR20260015342A (ko) 2017-07-21 2026-02-02 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1682740A (zh) * 2005-03-11 2005-10-19 中国药科大学 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
WO2007141390A1 (en) * 2006-06-07 2007-12-13 Valtion Teknillinen Tutkimuskeskus Betulin derived compounds useful as antiviral agents
TW200837074A (en) * 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2011100308A1 (en) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
WO2012037320A2 (en) * 2010-09-16 2012-03-22 Glaxosmithkline Llc Pharmaceutical compositions
CN105008322A (zh) * 2011-12-16 2015-10-28 葛兰素史克有限责任公司 白桦脂醇的衍生物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
EP1292562A1 (en) 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenoid derivatives
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1869063A2 (en) 2005-03-29 2007-12-26 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en) 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
UA97641C2 (xx) 2006-06-23 2012-03-12 Тиботек Фармасьютикелз Лтд. Водна суспензія 4-$$4-$$4-(2-ціаноетеніл)-2,6-диметилфеніл]аміно]-2-піримідиніл]аміно]бензонітрилу (tmc278)$водная суспензия 4-$$4-$$4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила (тмс278)
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
CA2693044C (en) * 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
EP2250185A4 (en) 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
JP2011508747A (ja) * 2008-01-03 2011-03-17 バイロケム ファーマ インコーポレイテッド 新規のｃ−２１ケトルパン誘導体、それらの調製および使用
DE102008037025C5 (de) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ2008723A3 (cs) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglykosidy triterpenoidu, zpusob jejich prípravy a jejich použití jako lécivo
MX351942B (es) * 2008-12-11 2017-11-03 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
AU2012352129B2 (en) 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
US20150209273A1 (en) 2012-08-28 2015-07-30 Glaxosmithkline Llc Pharmaceutical Compositions
SG11201503807TA (en) * 2012-12-14 2015-06-29 Glaxosmithkline Llc Pharmaceutical compositions
KR20170056702A (ko) 2014-09-26 2017-05-23 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 지효성 약제학적 조성물

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
CN1682740A (zh) * 2005-03-11 2005-10-19 中国药科大学 五环三萜类化合物在制备糖原磷酸化酶抑制剂中的应用
WO2007141390A1 (en) * 2006-06-07 2007-12-13 Valtion Teknillinen Tutkimuskeskus Betulin derived compounds useful as antiviral agents
TW200837074A (en) * 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2011100308A1 (en) * 2010-02-11 2011-08-18 Glaxosmithkline Llc Derivatives of betulin
WO2012037320A2 (en) * 2010-09-16 2012-03-22 Glaxosmithkline Llc Pharmaceutical compositions
CN105008322A (zh) * 2011-12-16 2015-10-28 葛兰素史克有限责任公司 白桦脂醇的衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘丹等: "3种五环三萜类化合物及其衍生物抗艾滋病的研究进展", 《中草药》 *

Also Published As

Publication number Publication date
CL2015001660A1 (es) 2015-10-02
KR20150093819A (ko) 2015-08-18
US9795619B2 (en) 2017-10-24
HK1209638A1 (en) 2016-04-08
EP2931285A1 (en) 2015-10-21
ZA201503594B (en) 2018-11-28
EP2931285A4 (en) 2016-06-01
MX2015007563A (es) 2015-10-14
WO2014093941A1 (en) 2014-06-19
IL238807A0 (en) 2015-06-30
SG11201503807TA (en) 2015-06-29
US20180042944A1 (en) 2018-02-15
CR20150313A (es) 2015-10-19
MA38182A1 (fr) 2018-04-30
PE20151326A1 (es) 2015-10-12
PH12015501156A1 (en) 2015-08-10
AU2013358897B2 (en) 2017-01-05
CA2893959A1 (en) 2014-06-19
AU2013358897A1 (en) 2015-07-02
JP2016503030A (ja) 2016-02-01
US20150313917A1 (en) 2015-11-05
BR112015013695A2 (pt) 2017-07-11
SG10201704467SA (en) 2017-06-29
EA201590862A1 (ru) 2016-05-31

Similar Documents

Publication Publication Date Title
AU2013358897B2 (en) Pharmaceutical compositions
US12138264B2 (en) Pharmaceutical compositions
US10092523B2 (en) Long acting pharmaceutical compositions
TWI389688B (zh) Vx-950之形態與調配物及其製備方法與用途
JP2006524190A5 (enExample)
JP2006290903A (ja) バラシクロビル層で被覆されたキャリアビーズを含んでなる医薬製剤
US20170312297A1 (en) Long Acting Pharmaceutical Compositions For Hepatitis C
KR20210137484A (ko) 캡시드 조립 조절제 고체 제형
JP4875205B2 (ja) チアジアゾール誘導体の安定な製剤
KR20240159619A (ko) 카리프라진 유리 염기 입자를 포함하는 주사용 디포우 제형
WO2025108980A1 (en) Intravenous administration of ticagrelor compositions in a patient who was previously administered an opioid in order to treat coagulation and avoid reduced ticagrelor uptake

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150909

WD01 Invention patent application deemed withdrawn after publication